Original Article

Treatment Failure in Cutaneous Leishmaniasis Patients Referred to the School of Public Health, Tehran University of Medical Sciences During 2008–2017

Abstract

Background: Cutaneous leishmaniasis (CL) is a vector borne disease predominantly found in tropical and subtropical countries, including Iran. For more than 6 decades, pentavalent antimonials have been used successfully worldwide for the treatment of leishmaniasis, but over the past few years, clinical resistance to these medications has increased. In this study, we evaluated CL patients who did not show any desirable responses to the anti-leishmanial treatment within a 10-year period (2008 to 2017).Methods: All patients from different parts of Iran suspected of having cutaneous leishmaniasis, who were referred to the laboratory of leishmaniosis in Tehran University of Medical Sciences from 2008–2017 were parasitological exam­ined.Results: During this period, a total of 1480 suspected CL patients were referred to the laboratory of leishmaniosis. Samples from 655 patients (70.8%) suspected of having CL were positive microscopically. The failure rate in patients treated with anti-leishmaniasis medications for a minimum of three complete treatment periods was 1.83% (12 cases). There was no association between the number and size of skin lesions and patient characteristics. Also, the route of drug administration had no significant effect on the number and size of lesions.Conclusion: In the present study, treatment failure was found in some confirmed CL patients treated with meglu­mine antimoniate. Over the past few years, it seems that had been increased in resistance to these medications. So, a review of the correct implementation of the treatment protocol and/or a combination therapy may be helpful in prevent­ing an increase in the rate of treatment failure.
1. World Health Organization (2014) Manual for case management of cutaneous leish-maniasis in the WHO Eastern Mediter-ranean Region. WHO Region¬al Publica-tions, Eastern Mediterranean Se¬ries (‎35). Available at: https://apps.who.int/iris/handle/10665/12000.
2. World Health Organization (2002) An in-creasing risk factor for leishmaniasis (Week¬ly Epidemiological Record. WHO Press. 77(44): 365–370.
3. Nadim A, Javadian E, Mohebali M, Zamen Moemeni A (2008) Leishmania and Leish¬maniasis in Iran, Second edition. Academic Publication Center, Tehran (In Per¬sian).
4. Ferreira FM, Castro RA, Batista MA, Rossi FMO, Silveria-Lemos D, Fre¬zard F, A.L.Moura S, Rezende SA (2014) As-sociation of water extract of green prop-olis and liposomal meglu¬mine an¬timoni-ate in the treatment of exper¬i¬mental vis-ceral leishmaniasis. Parasitol Res. 113 (2): 533–543.
5. Treatment and medical education of Iran (2002–2003) Diseases Management Cen¬ter, Ministry of Health, Treatment and Med¬ical Education. Annual Com-muni¬cable Diseases Report. Ministry of Health, Treatment and Medical Educa-tion Press, Iran.
6. Firdous R, Yasunzai M, Ranja K (2009) Efficacy of Glucantime® in the treat-ment of old world cutaneous leish¬mani-asis. Int J Dermatol. 48(7): 758–762.
7. Soleimanifard S, Arjmand R, Saberi S, Salehi M, Hejazi SH (2017) Treatment outcome of the drug-resistant zoonotic cutaneous leishmaniasis by Glucan-time®. Adv Bi¬omed Res. 6: 17.
8. Croft SL (2001) Monitoring drug re-sistance in leishmaniasis. Trop Med Int Health. 6(11): 899–905.
9. Croft SL, Sundar S, Fairlamb AH (2006) Drug resistance in leishmaniasis. Clin Microbiol Rev. 19(1): 111–126.
10. Hadighi R, Mohebali M, Boucher P, Haj-jaran H, Khamesipour A, Ouellette M (2006) Unresponsiveness to Glucan-time® treatment in Iranian Cutaneous leishman¬iasis due to drug resistant Leishmania tropica parasites. PLOS Medicine. 3(5): 162: 0659–0667.
11. Rodrigues AM, Hueb M, Santos TA, Fer-nandes CJ (2006) Factors associated with treatment failure of cutaneous leishmaniasis with meglumine anti¬mo-niate. Rev Soc Bras Med Trop. 39(2): 139–145.
12. Samady JA, Janniger CK, Schwartz RA (1996) Cutaneous and mucocutaneous leishmaniasis. Cutis. 57: 13–20.
13. Mohammadzadeh M, Behnaz F, Golshan Z (2013) Efficacy of Glucantime® for treatment of cutaneous leishmaniasis in central Iran. J Infect Public Health. 6(2): 120–124.
14. Hajjaran H, Mohebali H, Teimouri A, Oshaghi MA, Mirjalali H, Kazemi-Rad E, Shiee MR, Naddaf SR (2014) Identi-fication and phylogenetic rela¬tionship of Iranian strains of various and visceral cases of leishmaniasis based on N-acetyl¬glucosamin-1-phos¬phate transfer-ase gene. Infect Genet Evol. 26: 203–212.
15. Shirzadi MR (2012) Handbook of Cuta-neous Leishmaniasis Care in Iran. Ra¬zi Nahan Publication. (In Persian).
16. Magill AJ (2005) cutaneous leishmaniasis in the returning traveler. Infect Dis Clin North Am. 19(1): 241–266.
17. Holakouie-Naieni K, Mostafavi E, Dar-vishi Boloorani A, Mohebali M, Pakzad R (2017) Reprint of “Spatial modeling of cutaneous leishmaniasis in Iran from 1983 to 2013”. Acta Trop. 65: 90–95.
18. Killick-Kendrick R (1999) the biology and control of Phlebotominae sand flies. Clin Dermatol.17(3): 279–289.
19. Grogl M, Thomason TN, Franke ED (1992) Drug resistance in leishmania¬sis: its implication in systemic chem¬other¬apy of cutaneous and mucocuta¬neus diseas-es. Am J Trop Med Hyg. 47(1): 117–260.
20. Lira R, Sundar S, Makharia A, Kenney R, Gam A, Saraiva E, Sacks D (1999) Evi-dence that the high incidence of treat-ment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania do¬novani. J Infect Dis. 180(2): 546–547.
21. Gramiccia M, Gradoni L, Orsini S (1992) Decreased sensitivity to meglumine an-timoniate (Glucantime®) of Leish¬mania infantum isolated from Dogs after sev-eral courses of drug treat¬ment. Ann Trop Med Parasit. 86(6): 613–620.
22. Rojas R, Valderrama L, Valderrama M, Va¬rona MX, Ouellette M, Saravia NG (2006) Resistance to antimony and treatment fail¬ure in human Leishmania viannia infection. J Infect Dis. 193(10): 1375–1383.
23. Walker J, Gongora R, Vasquez JJ, Drum-melsmith J, Burchmore R, Roy G, Ouel-lette M, Gomez MA (2012) Dis¬covery of factors linked to antimony re¬sistance in Leishmania panamensis through dif-ferential proteome analysis. Mol Bio-chem Parasitol. 183(2): 166–176.
24. Khadem Erfan MB, Mohebali M, Kazemi-Rad E, Hajjaran H, Edrissian GH, Mamishi S, Saffari M, Raoofian R, Hei-dari M (2013) Downregulation of Cal-cineurin gene is associated with Glucan-time® resiatance in Leishmania infan-tum. Iran J Parasitol. 8(3): 359–366.
25. Ouellette M, Drummelsmith J, Papado-pou¬lou B (2004) Leishmaniasis: drugs in the clinic, resistance and new de¬vel¬op-ments. Drug Resist Updat. 7(4-5): 257–266.
26. Ghobakhloo N, Motazedian MH, Fardaei M (2016) Expression analysis of mul¬ti-ple genes may involve in antimony re-sistance among Lishmania major clinical isolates from Fars Prov¬ince, central Iran. Iran J Parasitol. 11(2): 168–176.
27. Do Monte-Neto RL, Coelho AC, Ray-mond F, Legare D, Corbeil J, Melo MN, Frezard F, Ouellette M (2011) Gene ex-pres¬sion profiling and molec¬ular char¬ac-ter¬ization of antimony re¬sistance in Leish¬mania amazonensis. PLOS Negl Trop Dis. 5(5): 1167.
28. Biyani N, Singh AK, Mandal S, Chawla B, Madhubala R (2011) Differential ex-pression of proteins in antimony-sus-ceptible and resistant isolates of Leish-mania donovani. Mol Biochem Parasi-tol. 179(2): 91–99.
29. Kazemi-Rad E, Mohebali M, Khadem-Erfan MB, Hajjaran H, Hadighi R, Khamesipour A, Rezaie S, Saffari M, Raoofian R, Hei¬dari M (2013) Over¬ex-pression of Ubiquitin and amino acid permease genes in association with an-timony resistance in Leishma¬nia tropica field isolates. Korean J Parasitol. 51(4): 413–419.
30. Kazemi-Rad E, Mohebali M, Khadem-Erfan MB, Saffari M, Raoofian R, Haj-jaran H, Hadighi R, Khamesipour A, Rezaie S, Abedkhojasteh H, Hei¬dari M (2013) Identification of anti¬mony re-sistance markers in Leishma¬nia tropica field isolates through cDNA–AFLP ap-proach. Exper Para¬sitol. 135(2): 344–349.
31. Zarean M, Maraghi S, Hajjaran H, Mohe-bali M, Feiz-Hadad MH, Assaehzade-gan MA (2015) Comparison of prote-ome pro¬filing of two sensitive and re-sistant field iranian isolates of Leish¬ma-nia major to Glucantime® by 2- dimen-sional electrophoresis. Iran J Parasitol. 10(1): 19–29.
32. Rassi Y, Jalali M, Vatandoost H (2000) Susceptibility status of Ph. papatasi to DDT in Arsanjan County in Fras Prov-ince, Iran. Iran J Public Health. 29(1–4): 21–23.
33. Rassi Y, Javadian E, Jalali M, Motazedian MH, Vatandoost H (2004) Investiga¬tion on zoonotic cutaneous leishmani¬asis, southern Iran. Iran J Public Health. 33 (1): 31–35.
34. Rassi Y, Javadian E, Amin M, Rafizadeh S, Vatandoost H, Motazedian H (2006) Meriones libycus, the principal reservoir of zoonotic cutaneous leish¬maniasis in southern Iran. Eastern Mediterr Health J. 12(3/4): 474–477.
35. Yaghoobi-Ershadi MR, Akhavan AA, Ja-hanifard E, Vatandoost H, Amin Gh, Moosa¬vi L, Zahraei Ramazani AR, Abdoli H, Arandian MH (2006) Re¬pel-lency effect of Myrtle essential oil and DEET against Phlebotomus pap¬tasi Scopoli, the main vector of zoon¬otic cu-taneous leishmaniasis under la¬bora¬tory conditions. Iran J Public Health. 35(3): 7–13.
36. Moosa-Kazemi SH, Shayeghi M, Abai MR, Vatandoost H, Sadeghi MT, Ja-vadian E, Motabar M, Hosseini MR, Abtahi M (2009) High performance thin layer chro¬matography analysis of del-tamethrin residue on the impreg¬nated bed nets during a Leishmaniasis control program in Iran. Iran J Arthro¬pod Borne Dis. 3(1): 1–7.
37. Oshaghi MA, Ravasan NM, Javadian E, Rassi Y, Sadraei J, Enayati AA, Vatan-doost H, Zare Z, Emami SN (2009) Ap-plication of predictive de¬gree day mod-el for field development of sandfly vec-tors of visceral leish¬maniasis in north-west of
Iran. J Vector Borne Dis. 46 (4): 247–55.
38. Aghaei Afshar A, Rassi Y, Sharifi I, Abai MR, Oshaghi MA, Yaghoobi-Ershadi MR, Vatandoost H (2011) Suscepti¬bil-ity status of Phlebotomus papatasi and P. sergenti (Diptera: Psychodidae) to DDT and Deltamethrin in a focus of Cutaneous Leishmaniasis after earth-quake strike in Bam, Iran. Iran J Ar-thropod Borne Dis. 5(2): 32–41.
39. Saeidi Z, Vatandoost H, Akhavan AA, Yaghoobi-Ershadi MR, Rassi Y, Sheikh Z, Arandian MH, Jafari R, Sanei-Dehkor¬di AR (2012) Baseline suscepti-bility of a wild strain of Phlebotomus papatasi (Diptera: Psy¬chodidae) to DDT and pyrethroids in an endemic fo-cus of zoonotic cutane¬ous leishmaniasis in Iran. Pest Manag Sci. 68(5): 669–675.
40. Veisi A, Vatandoost H, Yaghoobi-Ershadi MR, Arandian MH, Jafari R, Hosseini M, Abdoli H, Rassi Y, Heidari K, Sad-jadi A, Fadaei R, Ramazanpour J, Amini¬an K, Shirzadi MR, Akhavan AA (2012) Comparative study on the effec-tiveness of Coumavec and zinc phos-phide in con¬trolling zoonotic cu¬taneous leishmaniasis in a hyperen¬demic focus in central Iran. J Arthro¬pod Borne Dis. 6(1): 18–27.
41. Veysi A, Vatandoost H, Arandian MH, Jafari R, Yaghoobi-Ershadi MR, Rassi Y, Akhava AA (2013) Laboratory eval-uation of a rodenticide-insecticide, Couma¬vec®, against Rhombomys opi-mus, the main reservoir host of zo¬onotic cutaneouse leishmaniasis in Iran. J Ar-thropodBorne Dis. 7(2): 188–193.
42. Saeidi Z, Vatandoost H, Akhavan AA, Yaghoobi-Ershadi MR, Rassi Y, Aran-dian MH, Jafari R (2013) Base¬line in-secticide susceptibility data of Phleboto¬mus papatasi in Iran. J Vec¬tor Borne Dis. 50: 57–61.
43. Aghai Afshar A, Vatandoost H, Sharifi I, Rassi Y, Abai MR, Oshaghi MA, Yaghoobi-Ershadi MR, Rafizadeh S (2013) First determination of impact and outcome indicators following in-door residual spraying (IRS) with del-tamethrin in a new focus of anthro¬pon-otic cutaneous leishmaniasis (ACL) in Iran. Asian Pac J Trop Dis. 3(1): 5–9.
44. Aghai Afshar A, Rassi Y, Sharifi I, Vatan¬doost H, Mollaie HR, Oshaghi MA, Abai MR, Rafizadeh S (2014) First re¬port on natural Leishmania infec-tion of Phlebotomus sergenti due Leish-mania tropica by high resolution melt-ing curve method in South-eastern Iran. Asian Pa¬cific J Trop Med. 7(2): 93–96.
45. Akhavan AA, Veisi A, Arandian MH, Vatan¬doost H, Yaghoobi-Ershadi MR, Hosseini M, Abdoli H, Heidari K, Sad-jadi A, Fadaei R, Ramazanpour J, Aminian K, Shir¬zadi MR, Jafari R (2014) Field evaluation of phostoxin and zinc phosphide for the control of zoonotic cutaneous leish¬maniasis in a hyperendemic area, central Iran. J Vec-tor Borne Dis. 51(4): 307–312.
46. Jalilnavaz MR, Abai MR, Vatandoost H, Mohebali M, Akhavan AA, Zarei Z, Ra-fizadeh S, Bakhshi H, Rassi Y (2016) Application of flumethrin pour-on on res¬ervoir dogs and its effi¬cacy against sand flies in endemic fo¬cus of visceral leishmaniasis, Mesh¬kinshahr, Iran. J Ar-thropod Borne Dis. 10(1): 78–86.
47. Hazratian T, Vatandoost H, Oshaghi MA, Yaghoobi-Ershadi MR, Fallah E, Ra-fiza¬deh S, Shirzadi MR, Shayeghi M, Akbarzadeh K, Rassi Y (2016) Diver-sity of sand flies (Diptera: Psychodi¬dae) in endemic focus of visceral leishmani-asis in Azar shahr District, east Azarbai-jan Prov¬ince, North West of Iran. J Ar-thropod Borne Dis. 10(3): 328–334.
48. Sofizadeh A, Vatandoost H, Rassi Y, Hanafi-Bojd AA, Rafizade S (2016) Spatial Anal¬yses of the relation be¬tween rodent’s active burrows and in¬cidence of zoonotic cutaneous leish¬maniasis in Golestan Prov¬ince, North¬eastern of Iran. J Arthropod
Borne Dis. 10(4): 569–576.
49. Saghafipour A, Vatandoost H, Zahraei-Ram¬azani AR, Yaghoobi-Ershadi MR, Rassi Y, Shirzadi MR, Akhavan AA (2016) Spatial distribution of phlebotomine sand flies species (Dip-tera: Psychodidae) in Qom Province, central Iran. J Med Entomol. 54(1): 35–43.
50. Saghafipour A, Vatandoost H, Zahraei-Ram¬azani AR, Yaghoobi-Ershadi MR, Kara¬mi Jooshin M, Rassi Y, Shirzadi MR, Akha¬van AA, Hanafi-Bojd AA (2016) Epidemiological Study on Cu¬ta-neous Leish¬maniasis in an Endemic Ar-ea of Qom Province, Central Iran. J Ar-thropod Borne Dis. 11(3): 403–413.
51. Sofizadeh A, Rassi Y, Vatandoost H, Hanafi-Bojd AA, Mollalo A, Rafiza¬deh S, Akhavan AA (2016) Predicting the distribution of Phlebotomus papa¬tasi (Diptera: Psychodidae), the prima¬ry vec¬tor of zoonotic cutaneous leish¬mani-asis, in Golestan Province of Iran using Ecological Niche Modeling: Compari-son of MaxEnt and GARP Models. J Med Entomol. 54(2): 312–320.
52. Veysi A, Vatandoost H, Yaghoobi-Er-shadi MR, Jafari R, Arandian MH, Hos-seini M, Fadaei R, Ramazanpour J, Hei-dari K, Sad¬jadi A, Shirzadi MR, Akha-van AA (2016) Rodenticide com-parative effect of klerat® and zinc phosphide for controlling zoonotic cu-taneous leishmaniasis in central Iran. Iran J Parasito. 11(4): 471–479.
53. Saghafipour A, Vatandoost H, Zahraei-Ram¬azani AR, Yaghoobi-Ershadi MR, Rassi Y, Jooshin M, Shirzadi MR, Akhavan AA (2017) Control of zoon¬o-tic cutaneous leishmaniasis vector, Phlebotomus papatasi, using attractive toxic sugar baits (ATSB). PLOs One. 12(4): e0173558.
54. Shirani-Bidabadi L, Zahraei-Ramazani AR, Yaghoobi-Ershadi MR, Rassi Y, Akhavan AA, Oshaghi MA, Enayati AA, Saeidi Z, Jafari R, Vatandoost H (2017) As¬sessing the insecticide sus-ceptibility status of field population of Phlebotomus papatasi (Diptera: Psy-chodidae) in a hy¬perendemic area of zoonotic cutaneous leishmaniasis in Es-fahan Province, cen¬tral Iran. Acta Trop. 176: 316–322.
55. Arzamani K, Vatandoost H, Rassi Y, Abai MR, Akhavan AA, Alavinia M, Ak¬bar¬zadeh K, Mohebali M, Rfizadeh S (2017) Susceptibility status of wild population of Phlebotomus sergenti (Diptera: Psychodidae) to different ima-gicides in an endemic focus of cutane-ous leishmaniasis in northeast of Iran. J Vector Borne Dis. 54(3): 282–286.
56. Moradiasl E, Rassi Y, Hanafi-Bojd AA, Vatandoost H, Saghafipour A, Adham D, Aabasgolizadeh N, Omidi Oskouei A, Sadeghi H (2018) The relationship between climatic factors and the prev¬a-lence of visceral leishmaniasis in Northwest of Iran. Intern J Pediatrics. 2(50): 7169–7178.
57. Vatandoost H, Nejati J, Saghafipour A, Zahraei-Ramazani A (2018) Geo¬graphic and ecological features of phlebotomine sand flies (Diptera: Psy¬chodidae) as leish¬maniasis in Central Iran. J Parasitic Dis. 42(1): 43–49.
58. Karimian F, Vatandoost H, Rassi Y, Ma-leki-Ravasan N, Choubdar N, Koosha M, Arzamani K, Moradi-Asl E, Veysi A, Ali¬pour H, Shirani M, Oshaghi MA (2018) Wsp-based analysis of Wolbach-ia strains associated with Phlebotomus papatasi and P. sergenti (Diptera: Psy-chodidae) main cutane¬ous leishmaniasis vectors. Pathog Glob Health. 112(3): 152–160.
59. Arzamani K, Vatandoost H, Rassi Y, Akha¬van AA, Abai MR, Alavinia M, Akbarzadeh K, Mohebali M, Rafiza¬deh S (2018) Richness and diversity of phlebotomine sand flies (Diptera: Psy-chodidae) in North Khorasan Prov¬ince, northeast of Iran. J Arthropod Borne Dis. 12(3): 232–239
60. Karimian F, Vatandoost H, Rassi Y, Ma-leki-Ravasan N, Mohebali M, Shirazi MH, Koosha M, Choubdar N, Oshaghi MA (2019) Aerobic midgut microbi¬ota of sand fly vectors of zoonotic vis¬ceral leishman¬iasis from northern Iran, a step toward finding potential para¬transgenic candidates. Parasit Vectors. 12: 10.
61. Yaghoobi-Ershadi MR, Akhavan AA, Shir¬zadi MR, Rassi Y, Khamesipour A, Hanafi-Bojd AA, Vatandoost H (2019) Conducting international di¬ploma course on leishmaniasis and its control in the Is¬lamic Republic of Iran. J Ar-thropod Borne Dis. 13(3): 234–242.
62. Rassi Y, Moradi-Asl E, Vatandoost H, Ab¬azari M, Saghafipour A (2020) In-secti¬cide susceptibility status of wild popula¬tion of Phlebotomus kandelakii and Phleboto¬mus perfiliewi transcau¬ca-sicus collected from visceral leish¬mani-asis en¬demic foci in northwestern Iran. J Arthropod Borne Dis. 14(3): 277–285.
63. Yousefi S, Zahraei-Ramazani AR, Rassi Y, Vatandoost H, Yaghoobi-Ershadi MR, Aflatoonian MR, Akhavan AA, Aghaei-Afshar A, Amin M, Paksa A (2020) Eval¬uation of different attrac¬tive traps for capturing sand flies (Diptera: Psychodidae) in an endemic area of Leishmaniasis, Southeast of Iran. J Ar-thropod Borne Dis. 14(2): 202–213.
64. Moradi-Asl E, Mohebali M, Rassi Y, Vatan¬doost H, Saghafipour A (2020) Environ¬mental variables associated with distri¬bution of canine visceral leish-maniasis in dogs in Ardabil Province, Northwest¬ern Iran. Iran J Public Health. 49(6): 1033–1044.
65. Shirani-Bidabadi L, Zahraei-Ramazani AR, Yaghoobi-Ershadi MR, Akhavan AA, Oshaghi MA, Enayati AA, Rassi Y, Gholampour F, Shareghi N, Madreseh E, Vatandoost H (2020) Monitoring of Laboratory Reared of Phlebotomus papatasi (Diptera: Psy-chodidae), main vec¬tor of zoonotic cu-taneous leishmaniasis to different ima-gicides in hyper endemic areas, Esfahan Province, Iran. J Arthropod Borne Dis. 14(1): 116–125.
66. Mozaffari E, Vatandoost H, Rassi Y, Mohe¬bali M, Akhavan AA, Moradi-Asl E, Zarei Z, Zahrai-Ramazani A, Ghor-bani E (2020) Epidemiology of visceral leishmaniasis with emphasis on the dy-namic activity of sand flies in an im-portant endemic focus of disease in Northwestern Iran. J Arthro¬pod Borne Dis. 14(1): 97–105.
Files
IssueVol 14 No 4 (2020) QRcode
SectionOriginal Article
Published2021-01-03
DOI https://doi.org/10.18502/jad.v14i4.5274
Keywords
Cutaneous leishmaniasis; Anti-Leishmania drug; Treatment failure; Iran

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Kakooei Z, Hajjaran H, Akhoundi B, Charehdar S, Elikaee S, Shafeghat Z, Hassanpour H, Satvat MT, Kazemi-Rad E, Mohebali M. Treatment Failure in Cutaneous Leishmaniasis Patients Referred to the School of Public Health, Tehran University of Medical Sciences During 2008–2017. J Arthropod Borne Dis. 14(4):363–375.